Kolmar BNH accelerates its expansion in the European market with its technology-driven HemoHIM G

Kolmar BNH (KRX: 200130), a leading Korean health functional food development and manufacturing company, is accelerating its expansion efforts in Southeast Asia and Europe with HemoHIM G, a product designed for the global stage.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724688710/en/

HemoHIM G (Global) is the international version of “HemoHIM,” Korea’s first immune-boosting dietary supplement, developed by Kolmar BNH over a period of eight years. The formula has been adapted to comply with food regulations in various countries, with adjustments made to the raw materials and ingredient ratios. The product contains angelica sinensis, ligusticum chuanxiong, and paeonia lactiflora, all selected through rigorous quality control processes. The improved taste and aroma also make HemoHIM G more appealing to a wider audience.

In April, Kolmar BNH published a study on HemoHIM G in the SCIE-ranked journal Toxicological Research, demonstrating its safety. Conducted in accordance with OECD guidelines, the study is important not only to facilitate safety approvals in other countries, but also to strengthen intellectual property rights with reliable results.

HemoHIM, distributed by Atomy, is a technologically advanced product of Kolmar BNH. The main ingredient, HemoHIM Angelica Gigas Extract Complex, etc., was developed in collaboration with the Korea Atomic Energy Research Institute. It is currently available in 19 countries, including Australia, the United States, Thailand, Central Asia and South America.

Kolmar BNH continues its research and development efforts to improve HemoHIM’s global competitiveness, including investing approximately 4% of its annual sales in R&D. In June, the company published a study showing that the main ingredient of HemoHIM (Angelica gigas extract complex HemoHIM, etc.) has newly discovered antioxidant and anti-fatigue effects. This study was featured in the June issue of the “Journal of Medicinal Food”, an international SCIE-level journal.

Leveraging the competitive advantage of HemoHIM G, the company plans to accelerate its exports to European countries, including Turkey, Italy and Belgium.

A Kolmar BNH official said, “HemoHIM is one of the best-selling dietary supplements in Korea, with cumulative sales of KRW 200 billion over the past nine years since 2014. We aim to capitalize on our success in Korea and accelerate our expansion into the European market.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724688710/en/

Kolmar BNH

Jang Woo-Lee

Jay.lee@kolmar.co.kr

© Business Wire, Inc.

Disclaimer:
This press release is not a document published by AFP. AFP cannot be held responsible for its content. For any questions regarding this press release, please contact the contact/entity mentioned in the text of the press release.